Naveed Younis1, Steven Williams, Basil Ammori, Handrean Soran. 1. University Hospital South Manchester, Wythenshawe Hospital, Department of Diabetes & Endocrinology, Southmoor Road, Manchester M23 9LT, UK. naveed.younis@uhsm.nhs.uk
Abstract
OBJECTIVE: To evaluate the benefits of aspirin in people with diabetes mellitus for the primary prevention of cardiovascular disease. RESEARCH DESIGN/ METHODS: We searched MEDLINE and Cochrane database for randomized, controlled trials of aspirin in people with diabetes and no cardiovascular disease. Relative risks were determined using random-effects meta-analysis. MAIN OUTCOME MEASURES: Risk reduction of aspirin compared with control groups for major cardiovascular events. RESULTS: Six trials consisting of 7374 patients with diabetes showed no benefits of aspirin compared with non-aspirin users with regard to overall mortality, risk reduction (relative risk (RR) = 0.96, 95% CI 0.78 - 1.18, p = 0.71), major cardiovascular events (RR = 0.90, 95% CI 0.78 - 1.05, p = 0.17) and myocardial infarction (RR = 0.95, 95% CI 0.76 - 1.18, p = 0.63). Risk of major bleeding in the aspirin compared with the non-aspirin group was not significant (RR = 2.49, 95% CI 0.70 - 8.84, p = 0.16). CONCLUSIONS: Aspirin therapy did not reduce the risk of cardiovascular events. Existing trials were limited by small patient numbers and low cardiovascular event rates. The use of aspirin cannot be routinely recommended for primary prevention of cardiovascular events in diabetes.
OBJECTIVE: To evaluate the benefits of aspirin in people with diabetes mellitus for the primary prevention of cardiovascular disease. RESEARCH DESIGN/ METHODS: We searched MEDLINE and Cochrane database for randomized, controlled trials of aspirin in people with diabetes and no cardiovascular disease. Relative risks were determined using random-effects meta-analysis. MAIN OUTCOME MEASURES: Risk reduction of aspirin compared with control groups for major cardiovascular events. RESULTS: Six trials consisting of 7374 patients with diabetes showed no benefits of aspirin compared with non-aspirin users with regard to overall mortality, risk reduction (relative risk (RR) = 0.96, 95% CI 0.78 - 1.18, p = 0.71), major cardiovascular events (RR = 0.90, 95% CI 0.78 - 1.05, p = 0.17) and myocardial infarction (RR = 0.95, 95% CI 0.76 - 1.18, p = 0.63). Risk of major bleeding in the aspirin compared with the non-aspirin group was not significant (RR = 2.49, 95% CI 0.70 - 8.84, p = 0.16). CONCLUSIONS:Aspirin therapy did not reduce the risk of cardiovascular events. Existing trials were limited by small patient numbers and low cardiovascular event rates. The use of aspirin cannot be routinely recommended for primary prevention of cardiovascular events in diabetes.
Authors: Kunal N Karmali; Donald M Lloyd-Jones; Mark A Berendsen; David C Goff; Darshak M Sanghavi; Nina C Brown; Liliya Korenovska; Mark D Huffman Journal: JAMA Cardiol Date: 2016-06-01 Impact factor: 14.676
Authors: Joseph A Delaney; Nils Lehmann; Karl-Heinz Jöckel; Sammy Elmariah; Bruce M Psaty; Amir A Mahabadi; Matt Budoff; Richard A Kronmal; Khurram Nasir; Kevin D O'Brien; Stefan Möhlenkamp; Susanne Moebus; Nico Dragano; Almut G Winterstein; Raimund Erbel; Hagen Kälsch Journal: Atherosclerosis Date: 2013-05-14 Impact factor: 5.162
Authors: Yehuda Handelsman; Zachary T Bloomgarden; George Grunberger; Guillermo Umpierrez; Robert S Zimmerman; Timothy S Bailey; Lawrence Blonde; George A Bray; A Jay Cohen; Samuel Dagogo-Jack; Jaime A Davidson; Daniel Einhorn; Om P Ganda; Alan J Garber; W Timothy Garvey; Robert R Henry; Irl B Hirsch; Edward S Horton; Daniel L Hurley; Paul S Jellinger; Lois Jovanovič; Harold E Lebovitz; Derek LeRoith; Philip Levy; Janet B McGill; Jeffrey I Mechanick; Jorge H Mestman; Etie S Moghissi; Eric A Orzeck; Rachel Pessah-Pollack; Paul D Rosenblit; Aaron I Vinik; Kathleen Wyne; Farhad Zangeneh Journal: Endocr Pract Date: 2015-04 Impact factor: 3.443